Compare Gilead Sciences, Inc. (GILD) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Synopsys, Inc. — how do they compare? Gilead Sciences, Inc. trades at $135.34 (market cap $168.35B), while Synopsys, Inc. trades at $410.7 (market cap $78.68B). The key difference: Gilead Sciences, Inc. is far larger — about 2.1× Synopsys, Inc.'s market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| GILD | SNPS | |
|---|---|---|
Market Cap | $168.35B | $78.68B |
Sector | Health | Technology |
52-Week High | $155.80 | $625.80 |
52-Week Low | $110.56 | $372.33 |
Enterprise Value | $191.42B | $87.04B |
Dividend Yield | 2.42% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
